Last updated: September 6, 2026
Hetrombopag is a China-approved oral thrombopoietin receptor agonist developed by Jiangsu Hengrui Pharmaceuticals. Its commercial indications are chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The drug is marketed in China as hetrombopag olamine tablets, with the brand commonly identified as Hengqu. It is not approved by the U.S. FDA or European Medicines Agency as of June 2024.
The near-term opportunity is concentrated in China. Hetrombopag competes with eltrombopag and avatrombopag in ITP and SAA, but its international value remains limited until Hengrui establishes licensing, regulatory, and clinical-development partnerships outside China. A reasonable base-case projection is China sales of approximately RMB 500 million to RMB 900 million by 2028, subject to reimbursement access, hospital adoption, and pricing pressure.
What is hetrombopag and how does it work?
Hetrombopag olamine is an orally administered, nonpeptide thrombopoietin receptor agonist. It stimulates the thrombopoietin receptor, also known as MPL, on megakaryocyte-lineage cells and increases platelet production.
The product is pharmacologically related to eltrombopag but is a separate chemical entity. It is not a biosimilar and does not rely on an injectable biologic manufacturing platform.
| Attribute |
Hetrombopag |
| Active ingredient |
Hetrombopag olamine |
| Drug class |
Oral thrombopoietin receptor agonist |
| Primary developer |
Jiangsu Hengrui Pharmaceuticals |
| Dosage form |
Oral tablets |
| Main commercial market |
China |
| Initial approved indication |
Adult chronic ITP after inadequate response to prior therapy |
| Additional indication |
Severe aplastic anemia |
| U.S. approval |
None identified as of June 2024 |
| European approval |
None identified as of June 2024 |
| Main competitors |
Eltrombopag, avatrombopag, romiplostim |
Hetrombopag has a differentiated chemical structure from eltrombopag. The commercial rationale is to provide a domestic oral TPO-receptor agonist with potentially lower pricing than imported products and expanded access through China’s hospital and reimbursement systems.
What is the regulatory status of hetrombopag?
China’s National Medical Products Administration approved hetrombopag olamine tablets for adult patients with chronic ITP who had an inadequate response to other treatments in 2021. Hengrui subsequently obtained approval for use in SAA, expanding the addressable population beyond ITP. The approvals were based on Chinese clinical development programs evaluating platelet response and hematologic recovery.
The product does not have an identified FDA approval, biologics license application, or publicly established U.S. commercial launch. No European marketing authorization is identified in the public regulatory record through June 2024.
Regulatory status by market
| Market |
Status |
Commercial implication |
| China |
Approved for ITP and SAA |
Active commercial market |
| United States |
Not approved |
No U.S. product revenue |
| European Union |
Not approved |
No EU product revenue |
| Japan |
No major approval identified |
Limited direct access |
| Other Asia-Pacific markets |
No broad approval footprint identified |
Partnership-dependent opportunity |
The absence of U.S. and European approval sharply limits global revenue potential. International expansion would require additional clinical data, chemistry and manufacturing documentation, pharmacovigilance infrastructure, and country-specific reimbursement strategies.
What clinical development supports hetrombopag?
Hetrombopag’s clinical development has focused on platelet elevation in ITP and hematologic improvement in SAA.
In ITP, the development objective is durable platelet response sufficient to reduce bleeding risk and the need for rescue therapy. The relevant competitive benchmark is eltrombopag, which has an established treatment position in chronic ITP.
In SAA, the development opportunity is more specialized. Patients may require immunosuppressive therapy, hematopoietic stem-cell transplantation, or thrombopoietin-receptor agonist treatment. Eltrombopag has established evidence in SAA, making efficacy, tolerability, treatment sequencing, and price central to hetrombopag adoption.
Development strengths
- Oral administration
- Two approved hematology indications in China
- Domestic manufacturing and distribution infrastructure
- Potentially lower price than imported TPO-receptor agonists
- Use in diseases with chronic treatment requirements
Development limitations
- No established U.S. or EU development program
- Limited publicly visible global phase 3 activity
- Small patient populations relative to common hematology indications
- Competition from drugs with longer safety and efficacy histories
- Need for long-term data on thrombosis, marrow fibrosis, hepatotoxicity, and clonal evolution in SAA
How does hetrombopag compare with eltrombopag and avatrombopag?
Hetrombopag competes most directly with eltrombopag because both are oral small-molecule TPO-receptor agonists used in ITP and SAA. Avatrombopag is a more recent oral competitor with use in ITP and thrombocytopenia associated with chronic liver disease and procedures, depending on jurisdiction.
| Factor |
Hetrombopag |
Eltrombopag |
Avatrombopag |
| Administration |
Oral |
Oral |
Oral |
| China approval |
ITP and SAA |
Broad hematology use |
Approved in selected indications |
| Global approval |
Limited |
Extensive |
Extensive but narrower |
| SAA positioning |
Commercially relevant in China |
Established global position |
Less central |
| Food and mineral restrictions |
Product-specific |
Important calcium and polyvalent-cation restrictions |
Generally less restrictive |
| China pricing position |
Potentially competitive |
Imported and locally commercialized |
Competitive pressure varies |
| Clinical evidence depth |
Lower globally |
High |
High in approved indications |
| International access |
Limited |
Broad |
Broad |
Eltrombopag retains the evidence advantage. Hetrombopag’s strongest competitive argument is price and domestic availability rather than superior global clinical differentiation.
What is the market size for hetrombopag?
The primary market is China’s treated ITP and SAA population.
ITP is a chronic autoimmune platelet disorder. The commercially relevant population is smaller than total prevalence because not all patients require long-term TPO-receptor agonist treatment. Treatment persistence, line of therapy, reimbursement rules, and physician preference determine the usable market.
SAA is a smaller population but has higher treatment intensity. Drug demand can be concentrated among specialist hematology centers, particularly when patients are not transplant candidates, have relapsed disease, or require an alternative to conventional immunosuppression.
China market projection
The following projection is a scenario model rather than company guidance. It assumes continued reimbursement access, gradual hospital penetration, and price competition with eltrombopag.
| Year |
Estimated China net sales |
Main assumptions |
| 2023 |
RMB 150 million-300 million |
Early post-launch adoption |
| 2024 |
RMB 220 million-400 million |
Wider hospital listing and physician use |
| 2025 |
RMB 300 million-550 million |
Greater ITP penetration and SAA uptake |
| 2026 |
RMB 380 million-700 million |
Reimbursement scale and repeat treatment |
| 2027 |
RMB 450 million-800 million |
Mature specialist adoption |
| 2028 |
RMB 500 million-900 million |
Established domestic niche product |
A base case of approximately RMB 700 million in 2028 implies a compound annual growth rate of roughly 20% to 25% from a modeled 2024 base of RMB 275 million. The high case requires greater substitution from eltrombopag and strong SAA uptake. The low case reflects centralized purchasing, lower reimbursement prices, and increased competition from avatrombopag and other domestic TPO-receptor agonists.
Revenue sensitivity
| Variable |
Downside effect |
Upside effect |
| Reimbursement price |
Lower net sales despite volume growth |
Improved access and faster volume expansion |
| Hospital inclusion |
Slower physician adoption |
Broader prescribing |
| ITP persistence |
Lower annual treatment revenue |
More recurring revenue |
| SAA positioning |
Limited use after failed therapy |
Higher-value specialist use |
| Generic or local competition |
Price erosion |
Limited if product differentiation persists |
| Overseas licensing |
No additional revenue |
Milestone and royalty upside |
No reliable public evidence establishes a material revenue contribution from the United States or Europe. Any global projection should therefore assign international sales a low probability until Hengrui discloses regulatory filings or a regional licensing transaction.
What patents protect hetrombopag?
Hetrombopag is protected through a combination of compound, salt, formulation, process, and therapeutic-use rights. Public product information does not establish one universally applicable global patent-expiration date for all commercial claims.
The relevant patent categories are:
- Composition-of-matter patents covering the hetrombopag chemical structure.
- Salt and polymorph patents covering hetrombopag olamine and solid-state forms.
- Pharmaceutical-composition patents covering tablet formulations and excipients.
- Manufacturing patents covering synthesis, purification, crystallization, and scale-up.
- Method-of-use patents covering treatment of ITP, SAA, or platelet disorders.
- Regional patents that may have different filing dates, prosecution outcomes, and term adjustments.
The commercial strength of the estate depends on claim scope and the jurisdictions in which patents remain enforceable. A compound patent generally provides the strongest protection. Formulation and process patents may extend practical barriers but are more vulnerable to design-around strategies.
Orange Book status and generic entry
Hetrombopag has no identified U.S. FDA approval and therefore has no U.S. Orange Book listing associated with an approved product. U.S. Paragraph IV litigation is not a meaningful current commercial issue because a listed reference product and U.S. ANDA pathway have not been established.
In China, generic or competing-product risk is more relevant. Competitors could challenge compound, formulation, or use claims, or pursue regulatory development based on non-infringing processes and alternative dosage forms. The timing of entry will depend on Chinese patent expiration, invalidation proceedings, regulatory filing rules, and market access decisions.
What patent litigation and settlement agreements affect hetrombopag?
No major publicly reported U.S. patent litigation or Paragraph IV settlement involving hetrombopag was identified through June 2024. No material global settlement agreement has been publicly disclosed that would determine generic entry timing.
The principal legal risks are likely to arise in China from:
- Invalidity challenges to compound or salt claims
- Infringement disputes involving manufacturing routes
- Competing formulations
- Method-of-use claims for ITP and SAA
- Patent linkage or premarketing disputes involving follow-on products
The absence of disclosed litigation should not be interpreted as proof of a broad or weak patent estate. It indicates that the product’s commercial exposure remains centered on China and that public litigation records provide limited visibility.
How strong is the commercial and patent estate?
Hetrombopag has a moderate China commercial position and a weak-to-moderate global position.
Its commercial strengths are regulatory approval in two hematology indications, domestic production, and the ability to compete on price. Its principal weaknesses are limited geographic coverage, lower international clinical visibility, and established competition from eltrombopag.
Its patent strength cannot be rated as high without claim-level review of the Chinese and foreign families. The key distinction is between a surviving broad compound patent and narrower follow-on rights. Broad composition claims would support stronger exclusivity. Formulation and process claims alone would provide less protection against a technically capable competitor.
What generic launch risks exist?
The most likely launch scenario is continued domestic competition after patent or regulatory barriers weaken. Because hetrombopag is a small molecule, it does not face biosimilar competition. It faces conventional generic-drug and branded-generic risks.
Likely entry scenarios
- A competing oral TPO-receptor agonist captures price-sensitive hospital demand.
- A generic manufacturer challenges formulation or process claims.
- A domestic competitor uses an alternative synthesis route.
- Centralized procurement reduces the net price before patent expiry.
- Eltrombopag and avatrombopag retain specialist preference because of longer clinical histories.
- Hengrui protects share through reimbursement access, supply reliability, and lower pricing.
Manufacturing barriers are meaningful but not prohibitive. The active ingredient requires controlled chemical synthesis, impurity management, solid-state control, and validated tablet production. These requirements raise development and quality costs but do not create the biological manufacturing barriers associated with monoclonal antibodies.
What licensing deals could expand hetrombopag’s market?
No major publicly disclosed global licensing transaction was identified through June 2024. A licensing deal would be strategically important because Hengrui lacks a visible commercial footprint comparable to Novartis for eltrombopag or Sobi for avatrombopag.
The most logical targets would be:
- Southeast Asian markets with growing hematology capacity
- Latin American markets where lower-cost oral TPO-receptor agonists have value
- Middle Eastern markets with centralized procurement
- Selected European or U.S. development partnerships if additional clinical data support registration
A partner would likely require regional rights, regulatory control, manufacturing data, and a clear patent position. Without a partner, international expansion would require substantial investment in pivotal trials and commercial infrastructure.
Key Takeaways
- Hetrombopag is a China-approved oral TPO-receptor agonist developed by Jiangsu Hengrui.
- Its approved uses are chronic ITP and SAA.
- China is the only established commercial market as of June 2024.
- The drug competes primarily with eltrombopag and avatrombopag.
- A base-case China sales projection is approximately RMB 500 million to RMB 900 million by 2028.
- No U.S. FDA approval, Orange Book listing, Paragraph IV case, or major global settlement has been identified.
- Patent value depends on the surviving scope of compound, salt, formulation, process, and method-of-use claims.
- The drug is not exposed to biosimilar competition because it is a small molecule.
- International value depends on licensing or a new regulatory-development program.
- Pricing, reimbursement, hospital penetration, and domestic competition are the main commercial variables.
FAQs
Is hetrombopag approved in the United States?
No. Hetrombopag had no identified FDA approval or U.S. commercial launch as of June 2024.
Is hetrombopag a biosimilar to eltrombopag?
No. Hetrombopag is a separate small-molecule TPO-receptor agonist. It is not a biosimilar and is not structurally identical to eltrombopag.
Which diseases does hetrombopag treat?
Its China-approved indications are chronic immune thrombocytopenia and severe aplastic anemia.
What is the main commercial risk for hetrombopag?
The main risk is price and market-share pressure from eltrombopag, avatrombopag, and domestic Chinese competitors, compounded by reimbursement controls.
Could hetrombopag become a global product?
Yes, but global commercialization would require new regulatory filings, supporting clinical data, regional partners, and a defensible patent position outside China.
References
-
China National Medical Products Administration. (2021-2022). Drug approval and product information for hetrombopag olamine tablets. Beijing, China: NMPA.
-
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (2024). 2023 annual report. Lianyungang, China: Jiangsu Hengrui Pharmaceuticals.
-
U.S. Food and Drug Administration. (2023). Promacta (eltrombopag) prescribing information. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2023). Avatrombopag prescribing information. Silver Spring, MD: FDA.
-
ClinicalTrials.gov. (2024). Clinical studies of hetrombopag in immune thrombocytopenia and severe aplastic anemia. U.S. National Library of Medicine.